Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F25%3A00082400" target="_blank" >RIV/00159816:_____/25:00082400 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00142209 RIV/00216208:11110/25:10501615 RIV/61989592:15110/25:73631631 RIV/00064165:_____/25:10501615

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0924857925001372" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0924857925001372</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijantimicag.2025.107582" target="_blank" >10.1016/j.ijantimicag.2025.107582</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial

Popis výsledku v původním jazyce

Introduction: Colistin is recognized as the last-resort antibiotic for treating infections caused by multidrug-resistant Gram-negative bacteria, especially in critically ill patients. However, its interference with the extracorporeal membrane oxygenation (ECMO) circuit may affect the achievement of therapeutic targets. The COL-ECMO2022 study aimed to verify the interference of colistin and its prodrug colistimethanesulphonate (CMS) with ECMO. Methods: A prospective pharmacokinetic phase IV study included critically ill adults in whom the parenteral colistin was part of standard medical care. A maximum of three dosing intervals were monitored for each patient. CMS and colistin concentrations were measured by HPLC-MS. ECMO and non-ECMO patients were compared by average steady-state colistin concentration (CAVG,SS ), population pharmacokinetic model (ECMO as a covariate), and linear mixed-effect model (LMEM). Results: Eighteen patients and 40 monitored dosing intervals were analyzed. Median CAVG,SS was nonsignificantly lower in 7 patients on ECMO (4.3 [3.5-6.3] mg/L) than in 11 non-ECMO patients (5.2 [4.2- 11.5] mg/L) (by 18%; P = 0.551). ECMO was not a significant covariate for any pharmacokinetic parameter in the population PK model. Although LMEM proved significant adsorption of CMS on the ECMO circuit, colistin concentrations were not significantly influenced. Conclusion: No significant differences in colistin plasma concentrations were detected; therefore, CMS dosage adjustment is unnecessary in patients on ECMO. (c) 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Název v anglickém jazyce

Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial

Popis výsledku anglicky

Introduction: Colistin is recognized as the last-resort antibiotic for treating infections caused by multidrug-resistant Gram-negative bacteria, especially in critically ill patients. However, its interference with the extracorporeal membrane oxygenation (ECMO) circuit may affect the achievement of therapeutic targets. The COL-ECMO2022 study aimed to verify the interference of colistin and its prodrug colistimethanesulphonate (CMS) with ECMO. Methods: A prospective pharmacokinetic phase IV study included critically ill adults in whom the parenteral colistin was part of standard medical care. A maximum of three dosing intervals were monitored for each patient. CMS and colistin concentrations were measured by HPLC-MS. ECMO and non-ECMO patients were compared by average steady-state colistin concentration (CAVG,SS ), population pharmacokinetic model (ECMO as a covariate), and linear mixed-effect model (LMEM). Results: Eighteen patients and 40 monitored dosing intervals were analyzed. Median CAVG,SS was nonsignificantly lower in 7 patients on ECMO (4.3 [3.5-6.3] mg/L) than in 11 non-ECMO patients (5.2 [4.2- 11.5] mg/L) (by 18%; P = 0.551). ECMO was not a significant covariate for any pharmacokinetic parameter in the population PK model. Although LMEM proved significant adsorption of CMS on the ECMO circuit, colistin concentrations were not significantly influenced. Conclusion: No significant differences in colistin plasma concentrations were detected; therefore, CMS dosage adjustment is unnecessary in patients on ECMO. (c) 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30200 - Clinical medicine

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Antimicrobial Agents

ISSN

0924-8579

e-ISSN

1872-7913

Svazek periodika

66

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

107582

Kód UT WoS článku

001558990000001

EID výsledku v databázi Scopus

—